|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM366758837 |
| 003 |
DE-627 |
| 005 |
20240410232359.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
240114s2024 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2024.109892
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1371.xml
|
| 035 |
|
|
|a (DE-627)NLM366758837
|
| 035 |
|
|
|a (NLM)38185269
|
| 035 |
|
|
|a (PII)S1521-6616(24)00002-0
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chiu, Hui-Wen
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Guanylate binding protein 5 triggers NF-κB activation to foster radioresistance, metastatic progression and PD-L1 expression in oral squamous cell carcinoma
|
| 264 |
|
1 |
|c 2024
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 04.02.2024
|
| 500 |
|
|
|a Date Revised 10.04.2024
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2023. Published by Elsevier Inc.
|
| 520 |
|
|
|a Radioresistance and metastasis are critical issues in managing oral squamous cell carcinoma (OSCC). Although immune checkpoint inhibitors (ICIs) has been recommended to treat OSCC, lacking useful biomarkers limited their anti-cancer effectiveness. We found that guanylate binding protein 5 (GBP5) is upregulated in primary tumors and associates with radioresistance in OSCC. GBP5 expression causally associated with cellular radioresistance and migration ability in the OSCC cell variants. GBP5 upregulation was examined to be correlated with NF-κB activation and programmed cell death-ligand 1 (PD-L1) elevation in OSCC samples. GBP5 knockdown was mitigated, but overexpression enhanced, NF-κB activity and PD-L1 expression in the OSCC cells. NF-κB inhibition by SN50 dramatically suppressed the GBP5-forested irradiation resistance, cellular migration ability and PD-L1 expression in OSCC cells. Importantly, GBP5 upregulation predicted a favorable outcome in cancer patients received ICI treatment. Our findings provide GBP5 as a useful biomarker to predict the anti-OSCC effectiveness of irradiation and ICIs
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a GBP5
|
| 650 |
|
4 |
|a Metastasis
|
| 650 |
|
4 |
|a Oral squamous cell carcinoma
|
| 650 |
|
4 |
|a PD-L1
|
| 650 |
|
4 |
|a Radioresistance
|
| 650 |
|
7 |
|a B7-H1 Antigen
|2 NLM
|
| 650 |
|
7 |
|a Biomarkers
|2 NLM
|
| 650 |
|
7 |
|a NF-kappa B
|2 NLM
|
| 650 |
|
7 |
|a CD274 protein, human
|2 NLM
|
| 650 |
|
7 |
|a GBP5 protein, human
|2 NLM
|
| 700 |
1 |
|
|a Lin, Che-Hsuan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Hsun-Hua
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lu, Hsiao-Wei
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Yu-Hsien Kent
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lin, Yuan-Feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Lee, Hsin-Lun
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 259(2024) vom: 10. Feb., Seite 109892
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:259
|g year:2024
|g day:10
|g month:02
|g pages:109892
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2024.109892
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 259
|j 2024
|b 10
|c 02
|h 109892
|